Phase 3 Trial: VELOCITY

NOW ENROLLING: Pediatric Growth Hormone
Deficiency (GHD) Trial

Comparison of Long-acting Growth Hormone Somavaratan (VRS-317) to Daily Growth Hormone in Pediatric GHD Patients

XTEN Technology

New compounds developed using the XTEN technology are expected to provide improvement in outcomes such as enhanced efficacy, fewer side effects, improved patient adherence and convenience, and enhanced stability.

Our Team

We are committed to building a first class organization to develop and commercialize somavaratan (VRS-317) and, most importantly, change the lives of people living with the burden of daily injection therapy for the replacement of hGH.

About Versartis

Versartis is an endocrine-focused biopharmaceutical company initially developing novel, long-acting recombinant human growth hormone for the treatment of growth hormone deficiency.

Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN.

Clinical Trial Enrolling:

Somavaratan Phase 3 Global Trial

The VELOCITY trial is a randomized, one-year, open-label, multicenter, non-inferiority trial in pre-pubertal children with GHD comparing twice-monthly somavaratan (VRS-317) with daily rhGH, and is currently enrolling patients in the USA, Canada, Belgium, Netherlands, Poland and Sweden.

Latest News